Utility of PTEN and ERG Immunostaining for Distinguishing High-grade PIN From Intraductal Carcinoma of the Prostate on Needle Biopsy

Intraductal carcinoma of the prostate and high-grade prostatic intraepithelial neoplasia (PIN) have markedly different implications for patient care but can be difficult to distinguish in needle biopsies. In radical prostatectomies, we demonstrated that PTEN and ERG immunostaining may be helpful to resolve this differential diagnosis. Here, we tested whether these markers are diagnostically useful in the needle biopsy setting. Separate or combined immunostains were applied to biopsies containing morphologically identified intraductal carcinoma, PIN, or borderline intraductal proliferations more concerning than PIN but falling short of morphologic criteria for intraductal carcinoma. Intraductal carcinoma occurring with concurrent invasive tumor showed the highest rate of PTEN loss, with 76% (38/50) lacking PTEN and 58% (29/50) expressing ERG. Of biopsies containing isolated intraductal carcinoma, 61% (20/33) showed PTEN loss and 30% (10/33) expressed ERG. Of the borderline intraductal proliferations, 52% (11/21) showed PTEN loss and 27% (4/15) expressed ERG. Of the borderline cases with PTEN loss, 64% (7/11) had carcinoma in a subsequent needle biopsy specimen, compared with 50% (5/10) of PTEN-intact cases. In contrast, none of the PIN cases showed PTEN loss or ERG expression (0/19). On needle biopsy, PTEN loss is common in morphologically identified intraductal carcinoma yet is very rare in high-grade PIN. Borderline intraductal proliferations, especially those with PTEN loss, have a high rate of carcinoma on resampling. If confirmed in larger prospective studies, these results suggest that PTEN and ERG immunostaining may provide a useful ancillary assay to distinguish intraductal carcinoma from high-grade PIN in this setting.

[1]  J. Hicks,et al.  PTEN Loss is Associated with Upgrading of Prostate Cancer from Biopsy to Radical Prostatectomy , 2014, Modern Pathology.

[2]  M. Rubin,et al.  TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Magi-Galluzzi,et al.  Incidence and clinicopathological characteristics of intraductal carcinoma detected in prostate biopsies: a prospective cohort study , 2013, Histopathology.

[4]  J. Hicks,et al.  Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion , 2013, Prostate Cancer and Prostatic Diseases.

[5]  J. Hicks,et al.  Cytoplasmic PTEN Protein Loss Distinguishes Intraductal Carcinoma of the Prostate from High Grade Prostatic Intraepithelial Neoplasia , 2012, Modern Pathology.

[6]  J. Hicks,et al.  An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy , 2012, Cancer.

[7]  R. Shah,et al.  Atypical Cribriform Lesions of the Prostate: Clinical Significance, Differential Diagnosis and Current Concept of Intraductal Carcinoma of the Prostate , 2012, Advances in anatomic pathology.

[8]  J. Hicks,et al.  Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer , 2012, Modern Pathology.

[9]  T. H. van der Kwast,et al.  Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy. , 2012, European journal of cancer.

[10]  Jianfeng Xu,et al.  PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients , 2011, Clinical Cancer Research.

[11]  J. Hicks,et al.  Immunohistochemistry for ERG Expression as a Surrogate for TMPRSS2-ERG Fusion Detection in Prostatic Adenocarcinomas , 2011, The American journal of surgical pathology.

[12]  J. Epstein,et al.  Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy: emphasis on radical prostatectomy findings. , 2010, The Journal of urology.

[13]  F. Deng,et al.  Detection of TMPRSS2 Gene Deletions and Translocations in Carcinoma, Intraepithelial Neoplasia, and Normal Epithelium of the Prostate by Direct Fluorescence In Situ Hybridization , 2010, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[14]  K. Do,et al.  Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification. , 2010, European urology.

[15]  R. Shah,et al.  ETS Gene Aberrations in Atypical Cribriform Lesions of the Prostate: Implications for the Distinction Between Intraductal Carcinoma of the Prostate and Cribriform High-grade Prostatic Intraepithelial Neoplasia , 2010, The American journal of surgical pathology.

[16]  R. Shah,et al.  Atypical Cribriform Lesions of the Prostate: Relationship to Prostatic Carcinoma and Implication for Diagnosis in Prostate Biopsies , 2010, The American journal of surgical pathology.

[17]  L. True,et al.  Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer. , 2010, American journal of clinical pathology.

[18]  R. Shah,et al.  Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression , 2009, Modern Pathology.

[19]  C. Sander,et al.  Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis , 2009, Nature Genetics.

[20]  Pier Paolo Pandolfi,et al.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate , 2009, Nature Genetics.

[21]  O. Ludkovski,et al.  Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome , 2008, Modern Pathology.

[22]  R. Grobholz,et al.  Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate , 2008, Genes, chromosomes & cancer.

[23]  M. Loda,et al.  Characterization of TMPRSS2-ERG Fusion High-Grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications , 2008, Clinical Cancer Research.

[24]  Jonathan Ira Epstein,et al.  Biopsy Interpretation Of The Prostate , 2007 .

[25]  M. Rubin,et al.  A proposal on the identification, histologic reporting, and implications of intraductal prostatic carcinoma. , 2007, Archives of pathology & laboratory medicine.

[26]  J. Epstein,et al.  Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance , 2006, Modern Pathology.

[27]  J. Epstein,et al.  Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. , 2006, The Journal of urology.

[28]  J. McNeal,et al.  Distinction between intraductal carcinoma of the prostate (IDC‐P), high‐grade dysplasia (PIN), and invasive prostatic adenocarcinoma, using molecular markers of cancer progression , 2000, The Prostate.

[29]  J. McNeal,et al.  Patterns of differentiation and proliferation in intraductal carcinoma of the prostate: Significance for cancer progression , 2000, The Prostate.

[30]  J. Epstein.  Atypical small acinar proliferation of the prostate gland. , 1998, The American journal of surgical pathology.

[31]  M. Rubin,et al.  Cribriform carcinoma of the prostate and cribriform prostatic intraepithelial neoplasia: incidence and clinical implications. , 1998, The American journal of surgical pathology.

[32]  R. Cohen,et al.  Prediction of pathological stage and clinical outcome in prostate cancer: an improved pre-operative model incorporating biopsy-determined intraductal carcinoma. , 1998, British journal of urology.

[33]  J. McNeal,et al.  Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations. , 1996, The American journal of surgical pathology.

[34]  J. Kovi,et al.  Ductal spread in prostatic carcinoma , 1985, Cancer.